Antonella Bacchiocchi
Research Associate DermatologyDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Research Associate Dermatology
Departments & Organizations
- Halaban Lab
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Antonella Bacchiocchi's published research.
Publications Timeline
A big-picture view of Antonella Bacchiocchi's research output by year.
Ruth Halaban, PhD
Mario Sznol, MD
Harriet Kluger, MD
David F. Stern, PhD
Douglas E Brash, PhD
Qin Yan, PhD
40Publications
5,251Citations
Publications
2026
Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies
Lahav C, Dahan N, Harel M, Elon Y, Sela I, Geyer P, Schneider M, Muley T, Bacchiocchi A, Marte J, Floudas C, Halaban R, Sznol M, Christopoulos P, Gulley J. Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies. Journal Of Pharmaceutical And Biomedical Analysis 2026, 274: 117421. PMID: 41713118, PMCID: PMC13008497, DOI: 10.1016/j.jpba.2026.117421.Peer-Reviewed Original ResearchAltmetricClonal determinants of organotropism and survival in metastatic uveal melanoma
Jones B, Hammes E, Demkowicz P, Matesva M, Pointdujour-Lim R, Sinard J, Bacchiocchi A, Halaban R, Bosenberg M, Sznol M, Kluger H, Bakhoum M. Clonal determinants of organotropism and survival in metastatic uveal melanoma. Npj Precision Oncology 2026, 10: 68. PMID: 41582235, PMCID: PMC12913882, DOI: 10.1038/s41698-026-01274-8.Peer-Reviewed Original ResearchAltmetric
2025
CTLA-4 blockade shifts the B cell repertoire towards autoimmunity
Çakan E, Wang M, Dai Y, Mirouse A, Villanueva-Pachas C, Bouis D, Boeckers J, Gera R, Yraita S, Clapp L, Perdigoto A, Delmotte F, Massad C, Bacchiocchi A, Ring A, Kluger Y, Kluger H, Herold K, Meffre E. CTLA-4 blockade shifts the B cell repertoire towards autoimmunity. Journal Of Clinical Investigation 2025, 135: e189074. PMID: 41026527, PMCID: PMC12618075, DOI: 10.1172/jci189074.Peer-Reviewed Original ResearchCitationsAltmetricLZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis
Bacchiocchi A, Mak M, Khan Z, Gong X, Sznol M, Na Z, Su H, Chan L, Yan Q, Zhao D, Mortlock R, Knight J, Slavoff S, Halaban R. LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis. Oncogene 2025, 44: 3974-3984. PMID: 40885854, PMCID: PMC12500468, DOI: 10.1038/s41388-025-03538-2.Peer-Reviewed Original ResearchCitationsAltmetricThe ERVK3‑1 Microprotein Interacts with the HUSH Complex
Jayatissa A, Jaunbocus N, Erkalo B, Jiang K, Zheng S, Su H, Yan L, Choi J, Vaughan J, Bacchiocchi A, Na Z, Cao X, Halaban R, Saghatelian A, Craft J, Chen Y, Slavoff S. The ERVK3‑1 Microprotein Interacts with the HUSH Complex. Biochemistry 2025, 64: 3372-3381. PMID: 40699144, PMCID: PMC12339190, DOI: 10.1021/acs.biochem.5c00023.Peer-Reviewed Original ResearchCitationsBlocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors
Srivastava J, Yadav V, Jimenez R, Phadatare P, Inamdar N, Young M, Bacchiocchi A, Halaban R, Fang B, de Mingo Pulido A, Tsai K, Smalley K, Koomen J, Rodriguez P, Premi S. Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors. Cancer Research 2025, 85: 2268-2287. PMID: 40287947, PMCID: PMC12167936, DOI: 10.1158/0008-5472.can-24-0693.Peer-Reviewed Original ResearchCitationsAltmetricFAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
Lubrano S, Cervantes-Villagrana R, Faraji F, Ramirez S, Sato K, Adame-Garcia S, Officer A, Arang N, Rigiracciolo D, Anguiano Quiroz P, Martini C, Wang Y, Ferguson F, Bacchiocchi A, Halaban R, Coma S, Holmen S, Pachter J, Aplin A, Gutkind J. FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer Cell 2025, 43: 428-445.e6. PMID: 40020669, PMCID: PMC11903146, DOI: 10.1016/j.ccell.2025.02.001.Peer-Reviewed Original ResearchCitationsAltmetric
2024
Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma
Lu B, Lucca L, Lewis W, Wang J, Nogueira C, Heer S, Rayon-Estrada V, Axisa P, Reeves S, Buitrago-Pocasangre N, Pham G, Kojima M, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski J, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle A, Kisielow J, Obermair F, Kluger H, Hafler D. Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma. Nature Immunology 2024, 26: 82-91. PMID: 39609626, PMCID: PMC12285569, DOI: 10.1038/s41590-024-02023-4.Peer-Reviewed Original ResearchCitationsAltmetricUltra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Li X, Liu T, Bacchiocchi A, Li M, Cheng W, Wittkop T, Mendez F, Wang Y, Tang P, Yao Q, Bosenberg M, Sznol M, Yan Q, Faham M, Weng L, Halaban R, Jin H, Hu Z. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. EMBO Molecular Medicine 2024, 16: 2188-2209. PMID: 39164471, PMCID: PMC11393307, DOI: 10.1038/s44321-024-00115-0.Peer-Reviewed Original ResearchCitationsAltmetricPrognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Valdez C, Sánchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, Halaban R, Kulkarni R, Kang I, Bucala R, Tran T. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. Oncotarget 2024, 15: 507-520. PMID: 39028303, PMCID: PMC11259151, DOI: 10.18632/oncotarget.28615.Peer-Reviewed Original ResearchCitationsAltmetricMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkers, TumorFemaleHistocompatibility Antigens Class IIHumansImmune Checkpoint InhibitorsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMelanomaMiddle AgedMutationPrognosisRetrospective StudiesSkin Neoplasms
Get In Touch
Copy Link